drugset / Trial / NCT04447469
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Phase 2/3
Completed
814 enrolled
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals, Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
Timeline
- Start
- 2020-07-28
- Primary completion
- 2021-11-12
- Completion
- 2022-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mavrilimumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |